Abstract: A system which provides closed loop insulin administration is disclosed. The system includes redundant glucose sensors which may be interleaved in order to provide monitoring when one of the glucose sensors is in a settling period. The system may include a disease management unit which includes both a glucose sensor and an insulin pump. A closed loop disease management system which bases insulin administration on accurate glucose measurements may improve a patient's quality of life.

Abstract: The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

Abstract: A composition comprising a polypeptide ligated to an oligonucleotide through a sterol linker. A method of ligating a polypeptide to an oligonucleotide, comprising a polypeptide having a hedgehog steroyl transferase catalytic domain at the C-terminal of the polypeptide with an electrophilic residue, e.g., glycine, between polypeptide and the hedgehog steroyl transferase catalytic domain, and a steroylated oligonucleotide in solution, and permitting a reaction to cleave the hedgehog steroyl transferase catalytic domain from the polypeptide while ligating the steroylated oligonucleotide to the glycine at the C-terminal of the polypeptide. The oligonucleotide may be, for example, a therapeutic, diagnostic, or affinity ligand.

Abstract: Some embodiments of the invention include polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include nucleic acid molecules encoding polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include vectors comprising the nucleic acid molecule. Yet other embodiments of the invention include methods of using a myomerger polypeptide or an extracellular myomerger polypeptide. Additional embodiments of the invention are also discussed herein.

Abstract: Peptide docking vehicle compositions containing a therapeutic compound, such as an siRNA molecule, and a targeting ligand are provided, together with methods for their preparation and use. The compositions and methods allow targeted cell/tissue delivery of the therapeutic compound to a subject by linking a targeting ligand to the compound to provide enhanced therapeutic benefit. The subject may be an animal or a human.

Abstract: The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and comprises a biglycan as an active ingredient. Biglycan according to the present invention suppresses appetite by decreasing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.

Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.

Abstract: Provided is an engineered antimicrobial peptide. Also provided is a composition comprising an engineered antimicrobial peptide. Provided is a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of a composition comprising an engineered antimicrobial peptide. Also provided is a method of producing an engineered antimicrobial peptide.

Abstract: Adjuvant compounds are described, as well as their conjugates comprising peptide antigens or other immunomodulatory moieties. Also described are methods of modulating immune responses in a subject in need thereof, as well as methods of treating cancer, viral or bacterial infections comprising administering the adjuvant compounds or the conjugates to a subject in need thereof.

Abstract: One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

Abstract: A monoclonal antibody specifically binding to human and monkey CD38 antigens or a derivative thereof includes: antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region having amino acid sequences as set forth in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region having amino acid sequences as set forth in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable pharmaceutical preparation, administered alone or combined with other therapeutic means such as chemotherapy drugs, for treating tumors with positive CD38 expression, such as human myeloma and human lymphoma.

Abstract: A protein-rich composition can be provided from egg albumen via a process that involves diafiltering with purified water an egg albumen concentrate. Collected retentate from the diafiltration step constitutes a protein-rich composition which, on a dry basis, can include less than 1% (w/w) lipids. The composition can be spray dried to a protein isolate solid which is substantially free of sugars.

Abstract: The present invention provides a bilirubin nanoparticle formed by the self-assembly of bilirubin and a composite comprising a hydrophilic polymer, a use thereof, and a preparation method therefor. The bilirubin nanoparticle according to the present invention can release a drug enclosed therein to the outside by being collapsed by light or active oxygen stimulation. The bilirubin nanoparticle according to the present invention exhibits antioxidant, antiangiogenic, anticancer, and anti-inflammatory activities.

Abstract: Provided herein are synthetic bioconjugates comprising collagen-binding peptides covalently bound to chemically modified glycan backbones, compositions containing the same, and uses thereof.

Abstract: This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II: T1-f0-g0-a1-b1-c1-d1-e1-f1-g1-a2-b2-c2-d2-e2-f2-g2-a3-b3-c3-d3-e3-T2??(I) T3-g?0-a?1-b?1-c?1-d?1-e?1-f?1-g?1-a?2-b?2-c?2-d?2-e?2-f?2-g?2-a?3-b?3-c?3-d?3-e?3-f?3-T4??(II), as described in the present application. Methods of using these macrostructures are also disclosed.

Abstract: The disclosure describes a concentrate and a ready to use herbicide safener including 1-10 mg/L of glutamic acid, 10-100 mg/L of proline, and 50-200 mg/L of ?-Aminobutyric acid (GABA). The disclosure also concerns a method for protecting plants from herbicides. The method includes a step of applying a ready to use herbicide safener disclosed in the disclosure to a plant.

Abstract: An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.

Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.